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Abstract
Background: Bronchiolitis is a common respiratory illness of early childhood. For most children it is a mild self-limiting
disease but a small number of children develop respiratory failure. Nasal continuous positive airway pressure (nCPAP) has
traditionally been used to provide non-invasive respiratory support in these children, but there is little clinical trial evidence
to support its use. More recently, high-flow nasal cannula therapy (HFNC) has emerged as a novel respiratory support
modality. Our study aims to describe current national practice and clinician preferences relating to use of non-invasive
respiratory support (nCPAP and HFNC) in the management of infants (<12 months old) with acute bronchiolitis.
Methods: We performed a cross-sectional web-based survey of hospitals with inpatient paediatric facilities in England and
Wales. Responses were elicited from one senior doctor and one senior nurse at each hospital. We analysed the proportion
of hospitals using HFNC and nCPAP; clinical thresholds for their initiation; and clinician preferences regarding first-line
support modality and future research.
Results: The survey was distributed to 117 of 171 eligible hospitals; 97 hospitals provided responses (response rate: 83%).
The majority of hospitals were able to provide nCPAP (89/97, 91.7%) or HFNC (71/97, 73.2%); both were available at 65
hospitals (67%). nCPAP was more likely to be delivered in a ward setting in a general hospital, and in a high dependency
setting in a tertiary centre. There were differences in the oxygenation and acidosis thresholds, and clinical triggers such as
recurrent apnoeas or work of breathing that influenced clinical decisions, regarding when to start nCPAP or HFNC. More
individual respondents with access to both modalities (74/106, 69.8%) would choose HFNC over nCPAP as their first-line
treatment option in a deteriorating child with bronchiolitis.
Conclusions: Despite lack of randomised trial evidence, nCPAP and HFNC are commonly used in British hospitals to
support infants with acute bronchiolitis. HFNC appears to be currently the preferred first-line modality for non-invasive
respiratory support due to perceived ease of use.
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Background
Bronchiolitis is a common respiratory illness of young
childhood caused by viruses such as Respiratory Syn-
cytial Virus (RSV) [1]. Bronchiolitis is usually a mild,
self-limiting disease, but 2–5% of children require
hospitalisation [1–6], while 1–2.7% need critical care
support [7, 8].
Nasal continuous positive airway pressure (nCPAP)
has been used as a mode of non-invasive respiratory
support for infants with bronchiolitis-induced respira-
tory failure for over two decades [9–13], and is increas-
ingly being used in a ward setting [14]. Recently,
high-flow nasal cannula therapy (HFNC) has become a
popular alternative [15]. However, investment and train-
ing in new equipment is expensive, and concerns persist
regarding the safety of HFNC (risk of pneumothorax or
pneumomediastinum and nosocomial infection) and the
potential for delay in initiating invasive ventilation for
high-risk children [16–20].
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A previous survey of UK neonatal units demonstrated
widespread adoption of HFNC despite the absence of ro-
bust clinical trial evidence [21]. We aimed to establish
current national practice in the management of infants
with acute bronchiolitis by conducting a cross-sectional
survey of clinicians working in hospitals in England and
Wales. We also aimed to determine clinician preferences
regarding clinical triggers to initiate nCPAP and HFNC,
and to ascertain if clinical equipoise existed to support a
multicentre trial of non-invasive respiratory support in
acute bronchiolitis.
Methods
Survey
We designed a cross-sectional survey of hospitals with
inpatient paediatric facilities. An online questionnaire
using Survey Monkey software (www.surveymonkey.com,
Survey Monkey, Palo Alto, USA) was piloted by three se-
nior doctors from different parts of England (authors JP,
AS and JF). Feedback from the pilot was used to finalise
the questionnaire used in the study. The final question-
naire covered three main themes: availability and use of
nCPAP and HFNC at hospital level, clinical criteria for the
initiation of nCPAP and HFNC, and clinician preferences
towards future research. The final questionnaire is avail-
able as Additional file 1. Survey responses were elicited
using two methods: a) a survey link emailed to the lead
consultant and lead nurse in all 25 tertiary paediatric hos-
pitals and b) a survey link sent to each of the 12 regional
paediatric intensive care retrieval services, who were asked
to forward the questionnaire to the designated consultant
and senior nurse at each of the district general hospitals in
their regional network. Completion of the survey was
voluntary and consent was implied though completion
and submission of the survey. The initial survey
distribution was followed up by reminder emails 4
and 8 weeks later. Survey data were collected between
June and October 2014.
Data collected by the Royal College of Paediatrics and
Child Health for the Medical Workforce Census 2013
was used to provide data regarding the number and size
of all hospitals admitting children as in-patients in the
United Kingdom [22]. We used the definition of High
Dependency Care (HDC) as that defined in England and
Wales by the Royal College of Paediatrics and Child
Health: ‘care for a child who requires enhanced observa-
tion, monitoring or intervention than cannot be deliv-
ered on a standard paediatric ward’ [23]. The Royal
College of Nursing have published recommendations
for minimum nurse staffing levels for general paediat-
ric wards (1 nurse per 3 infants), high dependency
units (1 nurse per 2 patients) and intensive care units
(1 nurse per patient) [24].
Data analysis
We used the hospital as the unit of analysis for questions
relating to hospital practice. If discrepancies were identi-
fied between respondents from the same hospital, we
chose to use the senior doctor’s response for this ana-
lysis. We used the respondent as the unit of analysis for
questions relating to clinical thresholds and beliefs
regarding clinical equipoise. Results are reported as pro-
portions and/or means as appropriate. Significance
testing for differences in proportions were performed
using the chi-square test, and for differences in means
for normally distributed data using the Student t-test.
We performed multivariate analysis to study the associ-
ation between hospital type (tertiary vs. general hospital)
and the use of HFNC and/or nCPAP, respondent type
(consultant vs. nurse), preference of first-line modality
and willingness to participate in future research, using
the survey statistics module of Stata IC v13 (Stata
Corporation, College Station, USA). The hospital was set
as the primary sampling unit, and accounted for cluster-
ing of respondents within each hospital. Data analyses
were performed using Stata and Microsoft Excel (Microsoft
Corporation, USA).
Results
The survey was disseminated to 117 out of 171 eligible
hospitals; responses were obtained from 97 hospitals
(response rate: 83%). Survey responses were received
from all 25 tertiary hospitals. The survey was distributed
by regional PICU retrieval services to 8 out of 12 regions
in England and Wales, reaching 92 general hospitals, of
which 72 responded. Survey responses were provided by
159 individual respondents (mean: 1.6 responses per
hospital). The majority of respondents were paediatric
consultants (102/159, 64.2%) and the remainder were
senior nurses.
Characteristics of the hospitals from which responses
were obtained are shown in Table 1.
Availability of paediatric high dependency units (PHDU)
Most tertiary hospitals (88%) reported that they had a
dedicated PHDU compared to only 12.5% of general
hospitals, where children requiring high dependency
level care were more likely to be cared for in dedi-
cated PHDU beds located within the general ward
(57%). 26 general hospitals (26.8%) reported no avail-
ability of PHDU.
Guidelines and protocols
No guidelines were used by 5 hospitals for the man-
agement of bronchiolitis. The remainder used local,
regional and/or national guidelines. Overall, general
hospitals were more likely to use guidelines than
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tertiary hospitals. The majority of hospitals had local
guidelines in place (82/97, 84.5%).
Hospital practice regarding non-invasive respiratory support
in acute bronchiolitis
nCPAP
Twenty-four (96%) tertiary hospitals and 65 (90%) gen-
eral hospitals reported being able to provide nCPAP. Of
the 8 hospitals that did not use nCPAP, one commented
that there was a lack of evidence to support its use and
another that absence of adequate staff training prevented
its use. nCPAP was delivered in a ward setting by 4 out
of 25 (16%) tertiary hospitals and 41 out of 72 (56.9%)
general hospitals, whereas it was more likely to be deliv-
ered in a PHDU or PICU setting in a tertiary centre.
Use of sedation to facilitate the provision of nCPAP
was elicited from individual responders by asking them
how often sedation was used: always, sometimes, rarely
or never. Use of sedation was variable: 41/97 hospitals
used sedation sometimes or routinely (42.3%) while 37/
97 (38.1%) used it rarely. Nine hospitals reported never
using sedation, while 9 hospitals did not submit infor-
mation. Tertiary hospitals were more likely to use
sedation sometimes or routinely than general hospitals
(18/25, 72% versus 24/72, 33.3%, p = 0.003).
HFNC
Twenty (80%) of tertiary hospitals and 51 (70.8%) of
general hospitals reported being able to provide HFNC
(a further 9 hospitals were planning to implement the
technology within the next 12 months). HFNC was
delivered more frequently in the ward setting in general
hospitals (38/72, 52.8% vs. 6/25, 24%), whereas it was
more likely to be delivered in a HDU or PICU setting in
a tertiary centre (20/25, 80% vs. 20/72, 27.8%).
We asked responders about hospital guidelines for max-
imal flow rates for HFNC in particular areas of their hos-
pital. We used this as a reflection of safety concerns
regarding introduction of this new technology. Not all re-
sponders commented, however, there is a trend towards
higher flow rates being tolerated on paediatric wards and
high dependency areas than in emergency departments of
both tertiary and general hospitals (Table 2).
Either nCPAP or HFNC was available in all tertiary
hospitals and in nearly all general hospitals (70/72,
97.2%), while two-thirds of the hospitals had access to
both modalities (65/97, 67%).
Individual clinicians’ practice regarding non-invasive
respiratory support in acute bronchiolitis
Figure 1 illustrates oxygen requirement criteria that
clinicians currently use to initiate nCPAP and HFNC in
infants with acute bronchiolitis in tertiary hospitals
(panel A) and general hospitals (panel B). Fig. 2 illus-
trates acidosis criteria that clinicians currently use to
initiate nCPAP and HFNC in infants with acute bron-
chiolitis in tertiary hospitals (panel A) and general
hospitals (panel B). A significant number of clinicians
(see legends of Figs. 1 and 2) did not respond to these
two questions, citing that they would not use specific
oxygenation and acidosis criteria in isolation.
Figure 3 illustrates the clinical criteria of work of breath-
ing, recurrent apnoeas and presence of high-risk co-morbid
conditions (e.g., prematurity or cardiac disease) that influ-
ence the decision to initiate nCPAP and HFNC in tertiary
hospitals (panel A) and general hospitals (panel B).
Clinician preferences for first-line modality
In response to a clinical vignette describing a 6-month
old infant with acute bronchiolitis and respiratory dis-
tress, the majority of clinicians who had access to both
nCPAP and HFNC (74/106, 69.8%) reported that they
Table 1 Characteristics of hospitals who responded to the
survey (n = 97)
Tertiary centre
n = 25 (%)
General hospital
n = 72 (%)
Hospital sizea
Very small (≤1500 admissions per year) 1 (4.0) 2 (2.8)
Small (1501–2500 admissions per year) 4 (16.0) 14 (19.4)
Medium (1501–5000 admissions
per year)
9 (36.0) 34 (47.2)
Large (5001–6000 admissions per year) 3 (12.0) 9 (12.5)
Very large (>6000 admissions per year) 8 (32.0) 13 (18.1)
Care areas in hospital
Dedicated paediatric high dependency
unit
22 (88.0) 9 (12.5)
High dependency beds within
paediatric ward
4 (16.0) 41 (56.9)
No paediatric high dependency beds 3 (12.0) 23 (31.9)
Dedicated paediatric intensive care
beds
23 (92.0) 0 (0)
Dedicated paediatric emergency
department
18 (72.0) 12 (16.7)
Bronchiolitis guideline used
Local 20 (80.0) 62 (86.1)
Regional 3 (12.0) 13 (18.1)
National 2 (8.0) 13 (18.1)
No guideline 2 (8.0) 3 (4.2)
Availability of non-invasive respiratory support
nCPAP 24 (96.0) 65 (90.3)
HFNC 20 (80.0) 51 (70.8)
Either HFNC or nCPAP 25 (100) 70 (97.2)
Both 19 (76.0) 46 (63.9)
aClassification based on number of paediatric inpatient admissions per year
(as per the RCPCH Medical Workforce Census 2013)
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would start HFNC as the first-line treatment rather than
nCPAP. When asked what they perceived the role of
HFNC to be in clinical practice, many reported that they
considered it as an alternative to nCPAP (78/106, 73.5%)
or as a step up before nCPAP (84/106, 79.2%). A smaller
proportion felt that it was also useful as a step-down
therapy after discontinuation of nCPAP (63/106, 59.4%).
There were no significant differences between tertiary
hospitals and general hospitals in terms of clinician
preference for first-line support mode.
Future research
When asked to rate the importance of various outcome
measures to study in future research on a Likert scale
(1: least important; 5: most important), clinicians
rated reduction in the need for intubation and venti-
lation (mean score: 4.8 for general hospital respon-
dents and 4.5 for tertiary centre respondents, p = 0.01)
and avoiding transfer to another hospital (mean score:
4.7 for general hospitals and 4.0 for tertiary hospitals,
p < 0.001) as the most important (Table 3). Half of all
clinicians who responded were prepared to randomise
children with acute bronchiolitis to either nCPAP or
HFNC in a future clinical trial (80/159, 50.3%). An
additional 42 clinicians (26.4%) would consider par-
ticipation in an RCT, subject to the study design (free
text comments indicated that the ability to crossover
between treatment arms was an important consideration).
A
B
Fig. 1 Oxygen requirement threshold at which clinicians would start HFNC/nCPAP at tertiary hospitals (panel a) and general hospitals (panel b).
Graphs show a breakdown of available responses: panel a – 34 (NCPAP) and 29 (HFNC) responses from 50 clinicians; panel b – 64 (nCPAP) and
60 (HFNC) responses from 109 clinicians
Table 2 Maximal flow rates used locally for HFNC in tertiary and general hospitals
Tertiary Hospitals (n = 20) General Hospitals (n = 51)
1–5 L/min 6–10 L/min >10 L/min 1–5 L/min 6–10 L/min >10 L/min
Emergency Department 0 2 (10%) 0 2 (3%) 4 (7.8%) 7 (14%)
Paediatric Ward 0 5 (25%) 3 (15%) 3 (5.8%) 18 (35%) 18 (35%)
Paediatric High Dependency Ward 1 (5%) 6 (30%) 6 (30%) 5 (10%) 18 (35%) 13 (25%)
Turnham et al. BMC Pediatrics  (2017) 17:20 Page 4 of 8
A small proportion (9/159, 5.6%) reported that they were
unwilling to participate in a trial due to their belief in the
superiority of HFNC compared to nCPAP.
Multivariate analysis
Hospital type was not associated with the availability of
HFNC either on its own, or availability of both support
modalities, when adjusted for hospital size (p = 0.28 and
p = 0.17 respectively). Respondent type was not associ-
ated with choosing HFNC as first-line treatment or with
willingness to participate in a future trial, when adjusted
for hospital type and size (p = 0.65 and p = 0.89
respectively).
Generalisability
In order to assess the generalisability of our findings, we
compared the 54 general hospitals that were not sur-
veyed with the 72 hospitals that were surveyed – there
was no significant difference in the hospital size between
the two groups (p = 0.51). Similarly, we compared the 72
general hospitals that responded to the survey with the
25 hospitals that did not respond – there was no signifi-
cant difference in the hospital size (p = 0.53).
Discussion
Our national survey of hospitals reveals that the use of
nCPAP and HFNC is widespread in young children with
bronchiolitis. nCPAP appears to be used more frequently
in high dependency and intensive care areas, while
HFNC use is more frequent in paediatric wards. Clini-
cians appear to view HFNC and nCPAP as interchange-
able modalities, but HFNC appears to be their preferred
first-line support option.
nCPAP has been the traditional modality of respiratory
support for bronchiolitis for over two decades [9]. It
may help to maintain patency of small bronchioles, im-
prove secretion clearance, gas exchange and reduce work
of breathing [25]. Although small studies suggest a trend
A
B
Fig. 2 Acidosis threshold at which clinicians would start nCPAP/HFNC at tertiary hospitals (panel a) and general hospitals (panel b). Graphs show
a breakdown of available responses: panel a – 32 (NCPAP) and 26 (HFNC) responses from 50 clinicians; panel b – 70 (nCPAP) and 50 (HFNC) responses
from 109 clinicians
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towards physiological improvement with early nCPAP
use [12, 26], its impact on outcomes such as length of
hospital stay and need for intubation and invasive venti-
lation have yet to be confirmed in large randomised con-
trolled trials [27]. More recently, HFNC has increased in
popularity [15]. HFNC delivers a gas mixture of oxygen/
air, warmed to 34–37° Celsius with a relative humidity of
almost 100%, at high flow rates. It reduces airway resist-
ance, washes out end-expiratory gases and provides posi-
tive airway pressure, reducing work of breathing and
improving in gas exchange [28–30]. It is also well
tolerated [31].
Our survey findings are similar to those of a recent
survey of UK neonatal units −77% of neonatal units are
using HFNC, mainly as an alternative to nCPAP [21].
Similar findings have been reported from Australia and
New Zealand [32]. However, concerns regarding the
safety of HFNC, and reports that it may delay timely
access to invasive ventilation, do not support widespread
adoption without ensuring an adequate level of clinical
monitoring [17, 18].
Our survey results are important for several reasons.
First, this is the first national survey of current practice
in paediatrics relating to the use of non-invasive support
for acute bronchiolitis. Both nCPAP and HFNC are
available at most hospitals, but their use is variable and
A
B
Fig. 3 Clinical factors that influence decision to start nCPAP/HFNC at tertiary hospitals (panel a) and general hospitals (panel b)
Table 3 Patient outcomes viewed by clinicians as being important
for study in future research (reported as a score, 1 indicating least
important, 5 indicating very important)
Tertiary hospitals
(n = 50) Mean
(SD) score
General hospitals
(n = 109) Mean
(SD) score
Reduction of rate of intubation
and ventilation
4.5 (1.0) 4.8 (0.7)
Reduction in need for inter-
hospital transfer
4.0 (1.2) 4.7 (0.7)
Reduction in length of stay 3.9 (1.0) 4.2 (0.8)
Reduction in complication rate 3.9 (1.2) 4.3 (0.9)
Improved patient tolerance 3.9 (1.1) 4.2 (0.9)
Reduced need for sedation 3.6 (1.2) 3.5 (1.2)
Parent/Carer Satisfaction 4.0 (0.9) 3.9 (1.1)
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the clinical thresholds at which they are initiated are
often different. Second, despite limited evidence, we
have shown that HFNC appears to be the current pre-
ferred first-line support modality for infants with bron-
chiolitis. Third, despite enthusiasm for the use of HFNC,
the majority of respondents were in clinical equipoise
and were willing to participate in a future clinical trial,
but a small proportion were not, a number that is only
likely to rise in the face of increasing use and the
absence of forthcoming evidence. Future studies should
focus on clinical outcomes such as reduction in the need
for intubation and ventilation and/or need for inter-
hospital transfer.
Our survey had several strengths and limitations. We
chose for practical purposes to send the survey link first
to the regional retrieval services for onward dissemin-
ation, rather than directing it to each individual hospital.
Even though the survey link was sent to all 12 PICU
retrieval services, only 8 disseminated the survey to their
network hospitals, thereby resulting in lower coverage
than anticipated (54% of hospitals with inpatient paedi-
atric facilities). However, since this was not a systematic
process, it is unlikely to have resulted in significant bias.
Indeed, we showed that hospitals that were not surveyed
were similar to the ones that were surveyed, and that
responders were similar to non-responders. The high
survey response rate (83%) allows firm conclusions to be
drawn regarding current practice. It is also worth
highlighting that this was a self-reported questionnaire
and as such, may not reflect actual practice, for which
an audit of practice may be more useful. We also ac-
knowledge that we studied a rapidly evolving field where
clinical practice may already have changed since the sur-
vey was conducted.
Conclusions
Despite the paucity of supportive evidence, nCPAP and
HFNC are routinely used to support infants with acute
bronchiolitis. HFNC appears to be the preferred first-
line modality although the indications for its use and
clinical thresholds for its initiation are variable. There
remains sufficient equipoise among clinicians to support
a national randomised trial of non-invasive respiratory
support in acute bronchiolitis.
Additional file
Additional file 1: Survey questionnaire. (PDF 251 kb)
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